Agile Therapeutics (AGRX) Trading 7.9% Higher

Share on StockTwits

Shares of Agile Therapeutics Inc (NASDAQ:AGRX) traded up 7.9% on Thursday . The company traded as high as $0.97 and last traded at $0.96. 656,956 shares traded hands during trading, a decline of 62% from the average session volume of 1,731,310 shares. The stock had previously closed at $0.89.

A number of analysts have weighed in on the stock. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. HC Wainwright set a $4.00 target price on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $4.00.

The company has a market capitalization of $30.77 million, a price-to-earnings ratio of -1.10 and a beta of -0.95.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. On average, analysts expect that Agile Therapeutics Inc will post -0.6 EPS for the current year.

Several institutional investors have recently modified their holdings of AGRX. Fosun International Ltd bought a new stake in shares of Agile Therapeutics in the third quarter worth $180,000. Dimensional Fund Advisors LP grew its stake in shares of Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock worth $373,000 after purchasing an additional 55,937 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock worth $392,000 after purchasing an additional 343,290 shares during the last quarter. 51.92% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Agile Therapeutics (AGRX) Trading 7.9% Higher” was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: What is the balance sheet?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply